Advances with phospholipid signalling as a target for anticancer drug development.

G. Powis, M. Berggren, A. Gallegos, T. Frew, S. Hill, A. Kozikowski, R. Bonjouklian, L. Zalkow, R. Abraham, C. Ashendel

Research output: Contribution to journalReview article

Abstract

The phosphatidylinositol-3-kinases (PtdIns-3-kinase) are a family of enzymes involved in the control of cell replication. One member of the family, the mammalian p110/p85 PtdIns-3-kinase, is a potential target for anticancer drug development because of its role as a component of growth factor and oncogene activated signalling pathways. There are a number of inhibitors of this PtdIns-3-kinase, the most potent being wortmannin (IC50 4 nM). Wortmannin inhibits cancer cell growth and has shown activity against mouse and human tumor xenografts in mice. Other inhibitors of the PtdIns-3-kinase are halogenated quinones which also inhibit cancer cell growth and have some in vivo antitumor activity. Some D-3-deoxy-3-substituted myo-inositol analogues and their corresponding PtdIns analogues have been synthesized. They may act as myo-inositol antimetabolites in the PtdIns-3-kinase pathway and they can inhibit cancer cell growth.

Original languageEnglish (US)
Pages (from-to)395-403
Number of pages9
JournalActa biochimica Polonica
Volume42
Issue number4
DOIs
StatePublished - 1995

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Advances with phospholipid signalling as a target for anticancer drug development.'. Together they form a unique fingerprint.

  • Cite this

    Powis, G., Berggren, M., Gallegos, A., Frew, T., Hill, S., Kozikowski, A., Bonjouklian, R., Zalkow, L., Abraham, R., & Ashendel, C. (1995). Advances with phospholipid signalling as a target for anticancer drug development. Acta biochimica Polonica, 42(4), 395-403. https://doi.org/10.18388/abp.1995_4893